$4.18
+6.1%Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications
Compensation
$483,407
Chief Scientific Officer
Chief Technical Operations Officer
Compensation
$460,173
Founder & Director
Compensation
$1,659,751
President, Chief Executive Officer & Director
Compensation
$654,400
Senior Vice President of Legal & General Counsel
During the last 12 months, insiders have purchased $653K and sold $2.58M worth of WHWK shares, resulting in $1.93M of net selling activity.
0
0.00
695.8K
2.55M
-2.6M
-$2.55M
0
0.00
9.5K
31.53K
-32K
-$32K
0
0.00
0
0.00
+0
+$0
320.0K
652.90K
0
0.00
+653K
+$653K
Zhao Baiteng
Director
$82K
Reeve Emma
Director
$82K
Maroun Richard E
Director
$82K
Hirmand Mohammad
Director
$82K
Desai Neil
Director
$82K
Lennon David James
Director, Officer: Chief Executive Officer
$1.06M
Giacobello Scott M.
Officer: Chief Financial Officer
$891K
Ball Bryan
Officer: See Remarks
$635K
Strong bearish signal with $1.93M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
WHWK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 09, 2021 | July 22, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 24, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 18, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | May 15, 2018 | June 20, 2018 | 2018 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.